TORONTO, Sept. 8 /CNW/ - In a study published by The Lancet Journal
today, Toronto researcher Dr. Daniel Drucker reported that a new once-weekly
treatment for type 2 diabetes could replace the more common twice-daily
"Over two million Canadians have diabetes," said Dr. Daniel Drucker,
clinician-scientist and Senior Investigator at the Samuel Lunenfeld Research
Institute of Mount Sinai Hospital. "There is currently no available therapy
for type 2 diabetes that patients can receive once a week."
The new treatment, Exenatide once weekly is the first in a new class of
long-acting medications that mimic the action of GLP-1 (glucagon-like
peptide), a naturally occurring hormone that is produced in the gut after
eating. The report compared outcomes for patients self-injecting Exenatide
once weekly against results from the conventional 14 injections a week, as in
the currently available version of the drug known as Exenatide (Byetta).
In an international multicentre 6-month clinical trial involving 300
eligible patients, 75 per cent of study subjects who received the once-weekly
Exenatide got their diabetes under control as defined by reaching target
glucose levels. Patients treated with Exenatide once weekly also experienced
fewer side effects, had no increased risk of hypoglycemia (decrease in blood
sugars) and saw reductions in body weight.
Dr. Drucker has studied the gut hormone GLP-1 for over 20 years. Multiple
drugs based on GLP-1 action are under active clinical development, and the new
once-weekly treatment is expected to undergo Canadian regulatory review as
early as 2009.
"Biomedical research reaches patients and improves lives," said Dr. Jim
Woodgett, Director of Research at the Samuel Lunenfeld Research Institute.
"Dr. Drucker is a world-expert in the development of peptide hormone-based
therapies for the treatment of human disease and this is an excellent example
of moving discovery through to therapeutic application."
About the Samuel Lunenfeld Research Institute of Mount Sinai Hospital
The Samuel Lunenfeld Research Institute of Mount Sinai Hospital, a
University of Toronto affiliated research centre established in 1985, is one
of the world's leading centres in biomedical research. Thirty-two principal
investigators lead research in diabetes, cancer biology, epidemiology, stem
cell research, women's and infants' health, neurobiology and systems biology.
For more information on the Samuel Lunenfeld Research Institute, please visit
For further information:
For further information: Media Contacts: Nikki Luscombe, Communications
Specialist, Samuel Lunenfeld Research Institute Of Mount Sinai Hospital, Tel:
(416) 586-4800 x 2046, Email: firstname.lastname@example.org; Melissa McDermott, Media &
Communications Specialist, Mount Sinai Hospital, Tel: (416) 586-4800 x 7746,